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Background: Hepatic schistosomiasis is considered to be one of the most prevalent forms of chronic liver disease
in the world due to its complication of liver fibrosis. The demonstration of the pro-fibrogenic role of angiotensin
(Ang) II in chronic liver disease brought up the idea that anti-Ang II agents may be effective in improving hepatic
fibrosis by either blocking Ang II type 1 (AT1) receptors or inhibiting the angiotensin converting enzyme.
Peroxisome proliferator-activated receptors gamma (PPARγ) activation has been also shown to inhibit hepatic
stellate cell activation and progression of fibrosis. The present study has aimed at testing the anti-fibrogenic effects
of telmisartan; an AT1 receptor blocker and a PPARγ partial agonist, alone or combined with praziquantel (PZQ) on
Schistosoma mansoni-induced liver fibrosis in mice.
Methods: To achieve the aim of the study, two sets of experiments were performed in which telmisartan was
initiated at the 5th (set 1) and the 10th (set 2) weeks post infection to assess drug efficacy in both acute and chronic
stages of liver fibrosis, respectively. Schistosoma mansoni-infected mice were randomly divided into the following
four groups: infected-control (I), telmisartan-treated (II), PZQ-treated (III), and telmisartan+PZQ-treated (IV). In
addition, a normal non-infected group was used for comparison. Parasitological (hepatomesenteric worm load and
oogram pattern), histopathological, morphometric, immunohistochemical (hepatic expressions of matrix
metalloproteinase-2; MMP-2 and tissue inhibitor of metalloproteinase-2; TIMP-2), and biochemical (serum
transforming growth factor beta 1; TGF-β1 and liver function tests) studies were performed.
Results: Telmisartan failed to improve the parasitological parameters, while it significantly (P<0.05) decreased the
mean granuloma diameter, area of fibrosis, and serum TGF-β1. Additionally, telmisartan increased MMP-2 and
decreased TIMP-2 hepatic expression. Combined treatment failed to show any additive properties, yet it did not
affect the anti-schistosomal activity of PZQ.
Conclusions: These results suggest potential anti-fibrotic effects of telmisartan, an AT1 receptor blocker and a
PPARγ partial agonist, in acute and chronic stages of Schistosoma mansoni–induced liver fibrosis in mice.
Keywords: Hepatic fibrosis, Schistosoma mansoni, Telmisartan, MMP-2, TIMP-2, TGF-β1* Correspondence: yasmeen.attia@bue.edu.eg
1Department of Pharmacology and Biochemistry, Faculty of Pharmacy, The
British University in Egypt, Suez Desert Road, P.O. Box 43, El Sherouk City,
Cairo 11837, Egypt
Full list of author information is available at the end of the article
© 2013 Attia et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Attia et al. Parasites & Vectors 2013, 6:199 Page 2 of 12
http://www.parasitesandvectors.com/content/6/1/199Background
In recent years, there has been an increased recognition
of the importance of Neglected Tropical Diseases
(NTDs) as impediments to development. The World
Health Organization (WHO) has defined seventeen of
these conditions as core NTDs [1]. One of these NTDs
is schistosomiasis which is a major parasitic disease,
caused by blood flukes (trematode worms) of the genus
Schistosoma (S.), affecting millions of people worldwide.
It is endemic in about 76 countries and territories,
though it is estimated that 85% of the infected people
are on the African continent [2]. Chemotherapy with
praziquantel (PZQ) is the mainstay of schistosomiasis
control. Yet there are recent concerns about tolerance
or resistance to PZQ, and hence monitoring its efficacy
in different settings is required [3].
Inflammatory hepatic schistosomiasis, which is the
main cause of schistosomal hepatomegaly in children
and adolescents, is an early reaction to the ova trapped
in the perisinusoidal periportal spaces of the liver [4].
Peri-portal fibrosis is considered a serious consequence
of S. mansoni infection that involves remodeling of
extracellular matrix (ECM) and excessive deposition of
collagen, primarily by hepatic stellate cells (HSCs), along
the branches of the portal tract [5].
Over the last few years, HSCs have been commonly
recognized as the principal cell type responsible for
ECM protein formation during hepatic fibrogenesis, and
the cytokine transforming growth factor beta 1 (TGF-β1)
represents one key factor stimulating collagen and ECM
production in these cells [6]. The cytokine TGF-β1
promotes wound healing and repair. Under pathological
conditions, TGF-β1 orchestrates a cross talk between
parenchymal, inflammatory, and collagen-expressing cells
and plays a key role in stimulating fibrosis. Additionally,
overexpression of TGF-β1 in transgenic mice results in
fibrosis of multiple organs, suggesting that TGF-β1 is a
major pro-fibrogenic cytokine [7].
Complete recovery from liver fibrosis involves remodel-
ling and breakdown of multiple ECM components, with
degradation of the predominant component, collagen I,
being particularly important for recovery of normal liver
histology. An enlarging family of matrix metalloproteinases
(MMPs) was identified, which are calcium-dependent
enzymes that specifically degrade collagenous and
non-collagenous substrates [8]. Loebermann et al. [9]
reported that the expression of MMP-2 correlates
with both the onset and progression of fibrosis. However,
there is increasing evidence that collagenase inhibition
may arise from increased expression of endogenous MMP
inhibitors, tissue inhibitor of metalloproteinases (TIMPs)
in fibrotic liver. Expressions of both TIMP-1 and −2 were
found to be elevated in human and rat models of liver
fibrosis [10]. The resulting increase in TIMP:MMP ratioin liver may promote fibrosis by protecting deposited
ECM from degradation by MMPs [11].
The renin-angiotensin system (RAS) has been shown
to play a pivotal role in hepatic fibrogenesis [12]. A
common observation in most of the previous studies
is that liver injury is associated with an up-regulation
of RAS components including angiotensinogen, renin,
angiotensin converting enzyme, angiotensin (Ang) II,
and Ang II type-1 (AT1) receptors [13]. The balance
between ECM deposition and degradation, which de-
pends on the relative activity of MMPs and their in-
hibitors, TIMPs, was also found to be affected by hepatic
RAS. Following injury, AT1 receptor expression on acti-
vated HSCs is increased and these cells demonstrate
increased responsiveness to Ang II compared to quiescent
HSCs [14]. Angiotensin II has been shown to provoke
pro-fibrotic and pro-inflammatory effects on HSCs
including ECM production and fibrotic markers such
as α-smooth muscle actin and collagen, and the
expression of inflammatory cytokines and growth factors
such as TGF-β1 [12].
Peroxisome proliferator activated receptor gamma
(PPARγ) is a ligand-activated nuclear transcription factor
that belongs to the nuclear hormone receptor superfamily.
Hazra et al. [15] reported that PPARγ depletion is
associated with HSC activation, whereas increasing
PPARγ expression induces HSC quiescence and has
been found to inhibit activation markers such as α-smooth
muscle actin and collagen. Moreover, PPARγ receptors
were found to have anti-proliferative and anti-fibrotic
effects on activated HSCs as well as inducing HSCs
apoptosis through a mechanism involving an extrinsic
apoptosis pathway [16].
Previous studies have shown that telmisartan (TELM)
is distinguished from other members of AT1 receptor
blockers by its partial agonistic activity on PPARγ receptors,
which was previously reported to have anti-inflammatory
and anti-oxidant properties [17,18]. Accordingly, the
present study has been focused on investigating the poten-
tial effect of a drug with combined effects such as TELM,
an AT1 receptor blocker and a PPARγ activator, either




Swiss male albino mice of CD-1 strain, weighing 18–20 g
each, were provided by the Schistosome Biology Supply
Center (SBSC), Theodor Bilharz Research Institute (TBRI),
Giza, Egypt. They were fed on a standard diet with free ac-
cess to water at the animal house of the SBSC of TBRI.
The animals were kept under standard conditions of
temperature (25±0.5°C), relative humidity (55±1%) and
light cycle (12 h light and 12 h dark). All experiments
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ethical guidelines and were approved by the Ethics
Committee of the TBRI.Infection
An Egyptian strain of Schistosoma mansoni cercariae was
provided by the SBSC of TBRI. Cercariae were shed from
laboratory bred infected snails namely, Biomphalaria
alexandrina, 25–30 days after exposure to miracidia,
according to the method described by Pellegrino et al.
[19]. Infection was carried out by subcutaneous injection
of mice with 60±10 S. mansoni cercariae suspended in 0.2
ml solution [20].Drugs and doses
Praziquantel (E.I.P.I.Co. Pharmaceuticals, Cairo, Egypt)
was prepared as suspension in Cremophor-El and given
orally seven weeks post infection (WPI) at a dose of 500
mg/kg/day for two consecutive days [21]. Telmisartan
(Boehringer, Ingelheim, Germany) was given orally at a
dose of 10 mg/kg/day [22] for five weeks. In accordance
with the experimental design, it was started at either five
or ten WPI.Experimental design
Two sets of experiments were performed. In the first set,
TELM treatment was initiated five WPI and in the
second set, it was started ten WPI. In each set, infected
mice were randomly allocated to the following four groups,
each consisting of ten mice:Group I (infected control)
This group received only the drug vehicle, p.o.Group II (TELM-treated)
This group received TELM for five weeks.Group III (PZQ-treated)
This group received PZQ, seven WPI for two consecutive
days.Group IV (TELM+PZQ-treated)
This group received both TELM and PZQ as indicated
in groups II and III.
For comparison, a universal group (normal non-infected),
consisted of 20 mice (ten for each set) was used.
All animal groups belonging to either set of experiments,
were sacrificed by decapitation at the end of TELM
treatment for carrying out the selected parasitological,
histopathological, morphometric, immunohistochemical,
and biochemical studies.Parasitological studies
At the 10th and 15th WPI, all animals were sacrificed
and perfused using a Masterflex pump (Cole-Parmer
Instrument Company, USA). Worms recovered from the
hepatic and mesenteric compartments were collected
and counted. The anti-schistosomal effect of the drug was
assessed parasitologically by assessing the S. mansoni
hepatomesenteric worm load [23], and the oogram pattern
to determine the percentage of the different egg develop-
mental stages in the small intestines of mice [19].Biochemical studies
Blood samples collected from sacrificed mice were
allowed to stand for 30 min before centrifugation at
3000 rpm, for 15 min. Sera were then separated and
stored at −80°C for further estimation of:Alanine transaminase (ALT) and aspartate transaminase
(AST) enzyme activities
Serum levels of ALT and AST were estimated using the
available commercial kits (Roche Diagnostics, Germany).TGF-β1
Serum TGF-β1 was detected using an enzyme-linked
immunosorbent assay (ELISA) kit (R&D Systems, USA)
in accordance with the manufacturer’s instructions.Histopathological studies
Livers were excised from sacrificed mice, immediately
fixed in 10% formalin solution and embedded in paraffin.
Histological sections were processed and stained
with hematoxylin and eosin (H&E) to examine the
histopathological changes and with Masson’s Trichome to
measure the mean granuloma diameter (μm) using an
ocular micrometer (Zeiss, Germany), according to the
method described by von Lichtenberg [24].Morphometric Studies
Hepatic sections, 20 μm in thickness, were prepared and
stained with sirius red for the quantitation of the collagen
content using the computer-controlled Image Analysis
System (Leica, USA). Image analysis was performed using
the computer software program KS 200.
The sectional area of the red stained fibrous tissue of
the examined specimen was measured in squared
microns in five consecutive microscopic fields, at X125
magnification to yield the fibrotic area (μm2). Fibrotic
area relative to the total area (%) was then calculated as
described by Coutinho et al. [25]. For each group, the
results of all fibrotic areas (μm2) and fibrotic areas (%)
were then averaged.
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Hepatic sections, 4 μm in thickness, were mounted on glass
slides pre-treated with 3-amino propyl-triethoxy saline
(TESPA). The standard avidin-biotin immunoperoxidase
technique was used [26]. Hepatic paraffin sections were de-
waxed in xylene and hydrated in descending grades of etha-
nol. The endogenous peroxidase activity was quenched by
incubation in 100% methanol with 30% hydrogen peroxide
for 30 min. Antigen retrieval was performed by placing the
slides in a jar filled with 20 ml antigen retrieval solution
(Dako, Denmark) and 180 ml distilled water in a water bath
for 15 min of microwaves at 700 W. Sections were incu-
bated overnight at 4°C in a humid chamber with primary
antibodies against MMP-2 and TIMP-2 (Santa Cruz Bio-
technology, Santa Cruz, CA., USA). The antibodies
were diluted 1:100, 1:100, respectively, in phosphate
buffered saline (PBS). After rinsing in PBS, the sec-
tions were incubated at room temperature for 30 min
with biotinylated secondary anti-mouse antibody
(DAKO, Denmark) and after a further wash in PBS,
the slides were incubated with an avidin-biotin com-
plex horseradish peroxidase solution (DAKO,
Denmark) for another 30 min. Slides were then washed
with PBS for 5 min. After 10 minutes incubation, the per-
oxidase reaction was developed using 0.01% hydrogen per-
oxide in 0.05% diaminobenzidine tetrahydrochloride
(DAB). Sections were counterstained with Mayer's
hematoxylin and dehydrated in ascending grades of etha-
nol prior to mounting. Liver sections, with the primary
antibody replaced by PBS, served as negative controls,
while colonic cancer sections served as MMP-2 and
TIMP-2 positive controls. Immunostaining interpretation
of either MMP-2 or TIMP-2 was carried out according to
the method described by Sinicrope et al. [27]. Liver sec-
tions were examined using a light microscope (Zeiss,
Germany). The number of positively stained cells with theTable 1 Effects of 5 weeks treatment with telmisartan (TELM)
on hepatomesenteric worm load and oogram pattern (% egg










Male 5.25±0.12 5.75±0.51 1.17±0.08*@
Female 1.75±0.13 1.88±0.04 0.17±0.01*@
Couple 4.00±0.41 3.25±0.37 0.00±0.00*@
Total 15.00±1.08 14.25±0.88 1.33±0.12*@
% Egg developmental
stages
Immature 48.00±2.00 52.13±0.74 0.00±0.00*@
Mature 44.75±1.93 41.00±0.54 4.17±2.00*@
Dead 7.25±0.02 6.88±0.48 95.83±2.01*
Mice were infected with 60±10 cercariae/mouse, injected subcutaneously. Telmisart
weeks post infection for 5 weeks. Praziquantel (PZQ; 500 mg/kg/day, p.o.) was give
at the end of TELM treatment. Data are represented as mean ± S.E.M. (n = 8–10). Si
TELM-treated group.highest expression recorded within ten successive fields
(X400) was counted per section/animal in a semi-
quantitative way for both markers and their mean was
calculated. For each group, the mean percentages were
then averaged. Zero percentage was given to unstained
sections.
Statistical analysis
All values are presented as means ± S.E.M. Mean data from
each study group were compared by one-way analysis of
variance (one-way ANOVA). Chi-square test was used for
percent positivity. P values less than 0.05 were considered
to be statistically significant.
Results
Parasitological studies
At the 10th and 15th WPI, treatment with TELM alone
and combined with PZQ failed to cause any significant
changes in either the hepatomesenteric worm load or the
oogram pattern, as compared to the infected control and
PZQ-treated groups, respectively. However, PZQ treatment
caused significant reduction in the hepatomesentric worm
load; by 91.13 and 94.99%, at the 10th and 15th WPI,
respectively, as compared to the infected control groups.
Furthermore, at the 10th WPI, PZQ caused 100 and
90.68% reductions in both immature and mature egg
counts, respectively, as well as a 13.22-fold increase in dead
eggs, as compared to the infected control group. At the
15th WPI, treatment with PZQ showed 100 and 97.27%
reductions in immature and mature egg counts, respect-
ively, in addition to a 5.07-fold increase in the dead egg
count, compared to the infected control group (Table 1).
Biochemical studies
At the 10th and 15th WPI, the serum TGF-β1 measured
in the infected control groups revealed 2.62- and 4.04-foldgiven either alone or combined with praziquantel (PZQ)













0.72±0.03*@ 3.86±0.28 4.56±0.06 0.63±0.03* @ 1.10±0.09* @
0.14±0.01*@ 1.86±0.11 1.67±0.13 0.00±0.00*@ 0.00±0.00*@
0.00±0.00*@ 3.72±0.08 3.56±0.18 0.00±0.00*@ 0.00±0.00*@
0.86±0.03*@ 12.57±0.65 12.56±0.41 0.63±0.03*@ 1.10±0.08*@
0.00±0.00*@ 40.57±0.61 38.67±1.29 0.00±0.00*@ 0.00±0.00*@
3.29±0.01*@ 36.57±1.11 35.22±1.73 1.00±0.05*@ 0.70±0.02*@
@ 96.72±0.72*@ 19.58±1.56 20.33±0.67 99.13±0.44*@ 98.60±0.65*@
an (TELM; 10 mg/kg/day, p.o.) was given at the 5th (set 1) and 10th (set 2)
n at the 7th week post infection for 2 consecutive days. Animals were sacrificed














































Figure 1 Effect of telmisartan (TELM; 10 mg/kg/day, for 5 weeks), praziquantel (PZQ; 500 mg/kg/day, for 2 consecutive days), and their
combination on the serum levels of transforming growth factor β1 (TGF-β1) in ng/ml of Schistosma mansoni-infected mice sacrificed at
the 10th (set 1) and 15th (set 2) weeks post infection. All values are mean ± S.E.M. Significantly different (P<0.05) # versus normal non-infected
group, * versus infected control group and @ versus TELM-treated group.
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infected groups. Moreover, the S. mansoni infection caused
elevations in serum levels of ALT and AST by 1.6- and
2.33-fold at the 10th WPI, and by 2.01- and 2.18- fold at
the 15th WPI, respectively, compared to the normal non-
infected groups. TELM- and PZQ-treated groups showed
significant reductions in serum TGF-β1 by 17.37% and
41.66% at the 10th WPI and by 16.57% and 41.29% at the
15th WPI, respectively, compared to their corresponding
infected control groups. This showed that at the first and
second sets, the reductions in the serum TGF-β1 levels





























Figure 2 Effect of temisartan (TELM; 10 mg/kg/day, for 5 weeks), praz
combination on the serum levels of alanine transaminase (ALT) in U/L o
and 15th (set 2) weeks post infection. All values are mean ± S.E.M. Signif
* versus infected control group.2.49 fold than that observed with TELM. Treatment with
TELM combined with PZQ did not produce significant
reductions in serum TGF-β1 levels in both sets, when
compared to PZQ treatment alone (Figure 1).
At the 10th WPI, TELM- and PZQ-treated groups did
not show any significant change in serum ALT and AST
levels in comparison with the infected control group.
Moreover, combined treatment did not affect serum ALT
levels significantly, while it caused serum AST levels to
decrease by 34.52%, when compared to the infected
control group. However, at the 15th WPI, TELM- and








iquantel (PZQ; 500 mg/kg/day, for 2 consecutive days), and their
f Schistosma mansoni-infected mice sacrificed at the 10th (set 1)
































Figure 3 Effect of telmisartan (TELM; 10 mg/kg/day, for 5 weeks), praziquantel (PZQ; 500 mg/kg/day, for 2 consecutive days), and their
combination on the serum levels of aspartate transaminase (AST) in U/L of Schistosma mansoni-infected mice sacrificed at the 10th
(set 1) and 15th (set 2) weeks post infection. All values are mean ± S.E.M. Significantly different (P<0.05) # versus normal non-infected group,
* versus infected control group, @ versus TELM-treated group, and † versus PZQ-treated group.
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29.24%, respectively, compared to the infected control
group. Moreover, treatment with PZQ combined with
TELM decreased both ALT and AST serum levels by ap-
proximately 30%, compared to the infected control group
of the second set. It did not show any significant differ-
ences, however, when compared to the reductions ob-
served in the corresponding TELM- and PZQ-treated
groups (Figures 2 and 3).
Morphometric studies
As shown in Table 2, TELM- and PZQ-treated groups
showed reductions in the estimated fibrotic areas by
32.78 and 70.53% at the 10th WPI and by 43.06 and
54.75% at the 15th WPI, respectively, compared to theTable 2 Effects of 5 weeks treatment with telmisartan (TELM) gi
the mean granuloma diameter (μm), immunohistochemical expr
inhibitor of metalloproteinase-2 (TIMP-2) expressed as % of pos
fibrotic area relative to the total area examined of mice infected












286.33±5.07 240.10±11.41* 228.17±6.87* 234.
MMP-2 (%) 38.75±3.07 40.75±0.39 37.1±2.89 37.1
TIMP-2 (%) 24.75±1.70 5.75±0.96* 13.33±1.12*@ 6.38
Fibrotic area (μm2) 20.10±1.23 13.51±0.48* 5.92±0.67*@ 5.59
Fibrotic area (%) 7.36±0.17 4.94±0.29* 2.25±0.26*@ 2.14
Mice were infected with 60±10 cercariae/mouse, injected subcutaneously. Telmisart
weeks post infection for 5 weeks. Praziquantel (PZQ; 500 mg/kg/day, p.o.) was give
at the end of TELM treatment. Data are represented as mean ± S.E.M (n = 8-10). Sig
TELM-treated group, and † versus PZQ-treated group.corresponding infected control groups. At the 10th WPI,
the reduction in the area of fibrosis observed in the
PZQ-treated group was 2.82-fold higher than that
observed in the TELM-treated one. Combining TELM
with PZQ did not show any significant change in the fi-
brotic area measured, when compared to PZQ-treated
groups at both treatment periods.
Histopathological studies
At the 10th WPI, mice infected with S. mansoni showed
large fibrocellular granulomas in the hepatic parenchyma
with an outer zone of inflammatory cells mainly eosino-
phils, neutrophils, and lymphocytes and an inner zone of
fibrous tissue encircling the living bilharzial ova. The mean
granuloma diameter was found to be 286.33±5.07 μm.ven either alone or combined with praziquantel (PZQ) on
ession of matrix metalloproteinase-2 (MMP-2) and tissue
itively stained cells, and fibrotic area in μm2 and % of












72±5.54* 236.72±8.04 171.3±5.09* 158.25±7.38* 165.30±5.01*
8±2.91 9.29±0.07 39.45±3.27* 10.38±0.20@ 37.00±3.61*†
±0.49*@ 34.14±2.89 7.78±0.53* 32.88±3.05@ 8.58±0.81*†
±0.71*@ 12.75±1.01 7.26±0.56* 5.77±0.58* 5.82±0.88*
±0.27*@ 4.84±0.38 2.76±0.21* 2.20±0.21* 2.22±0.32*
an (TELM; 10 mg/kg/day, p.o.) was given at the 5th (set 1) and 10th (set 2)
n at the 7th week post infection for 2 consecutive days. Animals were sacrificed
nificant difference (P < 0.05) * versus infected control group, @ versus
Figure 4 (See legend on next page.)
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Figure 4 Immunostain for matrix metalloproteinase-2 (MMP-2; a) and tissue inhibitor of metalloproteinase-2 (TIMP-2; b) antibodies
(DAB, X200) of infected control liver sections of mice sacrificed at the 10th week post infection showing moderate and mild positively
stained hepatocytes and granuloma (fibroblast and inflammatory cells; arrows), respectively. Sections taken from livers of mice treated
with PZQ (500 mg/kg/day, p.o., for 2 consecutive days) showing moderate (a) and mild (b) positively stained hepatocytes, and granuloma cells
(arrows). Sections taken from livers of mice treated with telmisartan (10 mg/kg/day, p.o., for 5 weeks) showing moderate (a) and mild (b)
positively stained hepatocytes, and granuloma cells (arrows). Sections taken from livers of mice treated with PZQ combined with telmisartan
showing moderate (a) and mild (b) positively stained hepatocytes and granuloma cells (arrows).
Attia et al. Parasites & Vectors 2013, 6:199 Page 8 of 12
http://www.parasitesandvectors.com/content/6/1/199On the other hand, mice sacrificed at the 15th WPI showed
more granulomas deposited in the hepatic parenchyma
with more dense fibrous tissue and a decrease in the
inflammatory outer zone where the mean granuloma
diameter was found to be 236.72±8.04 μm (Table 2).
Telmisartan treatment showed a regression of the
granulomatous inflammatory reaction resulting in a
decrease in the mean diameter of the fibrocellular
granuloma at the 10th and 15th WPI by 16.15 and
27.64%, respectively, compared to the infected control
groups (Table 2).
Treatment with PZQ showed fibrocellular granulomas
formed of degenerated ova surrounded by giant cells,
pigmented macrophages, lymphocytes, plasma cells, and
fibrous tissue. Moreover, a decrease in the mean granu-
loma diameter was observed in the PZQ-treated groups
at the 10th and 15th WPI by 20.31 and 33.15%, respect-
ively, as compared to the infected control groups
(Table 2).
Combining PZQ with TELM did not produce any
significant change in the mean granuloma diameter
compared to either TELM- or PZQ-treated groups at
both treatment periods (Table 2).
Immunohistochemical studies
As can be seen in Figure 4, treatment with TELM started
at the 10th WPI failed to show any significant change in
MMP-2 hepatic expression, as compared to the infected
control group. However, it caused a 76.77% reduction in
TIMP-2 expression, compared to the infected control
group. PZQ treatment gave a similar pattern to that of
TELM. Thus, the drug did not significantly affect MMP-2
expression, as compared to the infected control group.
Meanwhile, a 46.14% reduction in TIMP-2 expression was
observed in the PZQ-treated group, as compared to the
infected control group. Treatment with PZQ combined
with TELM failed to cause any significant change in
MMP-2 expression, compared to the TELM- and
PZQ-treated groups, as well as TIMP-2 expression,
compared to the TELM-treated group (Table 2).
At the 15th WPI, treatment with TELM showed a
4.25-fold increase in MMP-2 expression and a reduction
in TIMP-2 expression by 77.21%, compared to the
infected control group. However, PZQ-treated groupfailed to show any significant change in the expression of
either MMP-2 or TIMP-2, as compared to the infected
control group. Administration of PZQ in combination with
TELM caused no significant change in either MMP-2 or
TIMP-2 expression, as compared to TELM-treated group
(Table 2; Figure 5).
Discussion
Hepatic schistosomiasis is considered to be one of the
most prevalent forms of chronic liver disease in the world,
resulting in morbidity due to complications of liver fibrosis.
However, there are few medicines or means available to
control and treat fibrosis resulting from schistosomiasis
[28]. The immunological response to oviposition in host
tissue, especially the liver, which leads eventually to hepatic
fibrosis, is considered to be a direct consequence of the
schistosomal pathology [29].
Renin angiotensin system blockers have been found to
alleviate hepatic fibrogenesis in various experimental
models [30-32]. Moreover, there are many studies now-
adays suggesting that PPARγ ligands play an important
role in inhibiting the progression of liver fibrosis by
exerting anti-proliferative and pro-apoptotic actions on
activated HSCs, the major collagen producers [16]. The
present study has aimed at testing the efficacy of TELM,
an AT1 receptor blocker and a PPARγ activator, in both
acute and chronic stages of liver fibrosis induced in mice
by S. mansoni infection.
In order to assess the parasitological efficacy of the
drugs being tested, both the hepatomesenteric worm
load and the oogram pattern were used. Treatment with
TELM alone failed to improve any of these parameters
in infected mice. This could be attributed to the absence
of any toxic effect exerted by TELM on either the eggs
trapped in the tissues or the intravascular worms. On
the other hand, the reductions in the hepatomesenteric
worm load as well as viable egg (mature and immature)
percentages observed with PZQ, either alone or combined
with TELM, are in agreement with previous studies in
which PZQ was used, either alone [33] or in combination
with a proposed enhancer such as Nigella sativa oil [34],
or dietary zinc supplement [35].
Mice that received TELM treatment showed significant
reductions in the mean granuloma diameters as well as the
Figure 5 (See legend on next page.)
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Figure 5 Immunostain for matrix metalloproteinase-2 (MMP-2; a) and tissue inhibitor of metalloproteinase-2 (TIMP-2; b) antibodies
(DAB, X200) of infected control liver sections of mice sacrificed at the 15th week post infection showing mild and moderate positively
stained hepatocytes and granuloma (fibroblast and inflammatory cells; arrows), respectively. Sections taken from livers of mice treated
with PZQ (500 mg/kg/day, p.o., for 2 consecutive days) showing mild (a) and moderate (b) positively stained hepatocytes, and granuloma cells
(arrows). Sections taken from livers of mice treated with telmisartan (10 mg/kg/day, p.o., for 5 weeks) showing moderate (a) and mild (b)
positively stained hepatocytes, and granuloma cells (arrows). Sections taken from livers of mice treated with PZQ combined with telmisartan
showing moderate (a) and mild (b) positively stained hepatocytes and granuloma cells (arrows).
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accordance with the results obtained by El-Lakkany et al.
[36] who showed that losartan, an AT1 receptor blocker,
resulted in some healing of the granulomatous hepatic
lesions in S. mansoni-infected mice as could be observed
from a reduction in the mean granuloma diameter.
The authors suggested an anti-inflammatory pathway
through which the drug might have suppressed the
immune-mediated reaction to oviposition. It was also
found that inhibition of Ang II produced changes in
the mechanisms of oxidative stress, especially at the
mitochondrial level, indicating an anti-inflammatory
effect [37]. Furthermore, the in vitro finding that AT1
receptors are expressed on activated human HSCs
and are, thus, likely to be increased in number as
stellate cells proliferate, and that the binding of Ang II to
these receptors induces contraction and proliferation of
these cells [14], provides evidence for a potential pathway
through which AT1 receptor blockers might alleviate
hepatic fibrosis. In addition, Hazra et al. [15] reported that
PPARγ depletion is associated with HSC activation, whereas
HSC quiescence is induced by increasing PPARγ expres-
sion, which has been found to inhibit activation markers
such as α-smooth muscle actin and collagen. Accordingly,
we can conclude that the reduction in the mean granuloma
diameter and the fibrotic area, as measures of the degree of
fibrosis, caused by TELM treatment, could be attributed to
the anti-inflammatory activity as well as its inhibitory effects
on HSCs activation, being an AT1 receptor blocker and a
PPARγ activator.
The reduction in the granuloma size, following PZQ
treatment, has been previously reported by Botros et al.
[38]. The authors noted a reduction in T-helper cells in
the bilharzial granuloma and stated that the granuloma
size reduction after PZQ treatment could be the result
of the inhibition of the inflammatory mediators released
locally at the site of the granulomatous inflammation.
Collagen turnover and ECM remodeling that occur
during various physiological and pathological processes
including tissue repair, wound healing, fibrosis, and
tumor invasion are largely dependent on the regulation
of MMP and TIMP activities [39]. In the current study,
liver sections of S. mansoni-infected mice belonging to
both sets, showed moderate expressions of both MMP-2and TIMP-2. This is because the expression of both genes
is up-regulated and mainly expressed by HSCs during
fibrogenesis. However, during liver fibrosis resolution, as
TIMP expression declines, the persistence of MMP-2 may
permit collagen degradation [40]. It was found that
MMP-2 expression increased and remained elevated
during experimental fibrogenesis induced by carbon
tetrachloride (CCl4) [41]. Yet, high levels of TIMP-2
in the fibrotic liver were capable of inhibiting active
MMP-2 [42].
TELM alone increased MMP-2 expression in the second
set, and decreased TIMP-2 expression significantly in both
sets. The study of Cheng et al. [39] showed that activating
PPARγ by curcumin treatment increased MMP-2 activity
significantly and that this effect was weakened by the spe-
cific PPARγ antagonist. In addition, Yu et al. [16]
demonstrated that PPARγ activation significantly reduced
expression levels of TIMP-2 in liver tissue suggesting that
it has dual inhibitory effects on HSC activation through
inhibiting collagen production and stimulating matrix
degradation. Thus, it can be concluded that the observed
elevation in MMP-2 and the decline in TIMP-2 expression
may have contributed to collagen degradation and a con-
sequent decrease in granuloma diameters and fibrotic
areas following TELM treatment.
PZQ treatment alone did not show significant elevation
in MMP-2 expression compared to infected controls of
both sets. Meanwhile, it caused a reduction in TIMP-2
expression at the 15th WPI while no change was observed
at the 10th WPI. These results are in agreement with the
study of Singh et al. [43], who showed that PZQ treatment
did not cause significant changes in MMP-2 expression in
S. mansoni-infected mice, whereas TIMP-2 expression
showed little or no change.
Previous studies have shown that in the evolution of
the granulomatous response to the S. mansoni eggs,
TGF-β1 is produced and may modulate inflammation
and hence regulate fibrogenesis [43,44]. In the current
study, TELM caused significant reductions in serum
TGF-β1 levels in both sets. A relevant study [32] showed
that olmesartan; an AT1 receptor antagonist, succeeded
in reducing plasma levels of TGF- β1 in bile duct-ligated
rats. Bataller et al. [12] also showed that Ang II is a po-
tent inducer of TGF-β1 production in cultured HSCs
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that there is a close relationship between Ang II and
TGF-β1. Accordingly, the current study reinforces the
prevailing hypothesis that TGF-β1 in fibrotic disease de-
pends, at least in part, on Ang II generation. Consistent
with the previous results, also is the study of Chen et al.
[28] who demonstrated that PPARγ ligand, rosiglitazone,
can reduce inflammation and liver fibrosis with Schistosoma
infection by reducing TGF-β1 expression.
Results of the current work revealed that the reductions
in serum TGF-β1 levels observed with PZQ were signifi-
cantly higher than those observed with TELM. This could
be attributed to the anti-helminthic activity of PZQ, which
leads to the death of viable eggs and prevents their
further deposition, which is considered to be the
triggering stimulus for the multiple signalling pathways
involved in the generation of TGF-β1 in this model.
Telmisartan, however, affects only two of these pathways
i.e. Ang II and PPARγ. The reduction in TGF-β1
levels elicited by PZQ is consistent with the studies
of Singh et al. [43]; El-Lakkany & Nosseir [44], and
El-Lakkany et al. [45] that revealed a marked drop
(amounting to 70% in the first study) in the TGF-β1
expression caused by PZQ in S. mansoni-infected mice.
In the current study, combined TELM and PZQ treat-
ment generally failed to show significantly better results
from using either TELM or PZQ alone, provided that the
former is given at a dose of 10 mg/kg/day for 5 weeks and
the latter is given early in a full curative dose (500 mg/kg/
day for 2 consecutive days) as previously mentioned.
Hence, this combination did not seem to have an added
benefit. This could be attributed to the reduction in egg
deposition caused by early PZQ treatment, which is the
injurious triggering stimulus for the activation of HSCs.
Consequently, this leads to the reduction in the expression
of AT1 receptors available for TELM blockade as well as
less reduction in PPARγ receptor expression. Thus, in a
combined regimen, early treatment with PZQ may have
reduced the anti-fibrotic effects observed when compared
to using TELM alone. However, a recent study [46] demon-
strated an anti-fibrotic effect of PZQ (300 mg/kg, given
twice daily for 30 days) at the 8th and 15th WPI in mice
with advanced chronic schistosomiasis as well as in
CCl4-induced liver fibrosis. Yet, further studies examining
the efficacy of combining TELM to PZQ, which may
require using different doses of both drugs, are
recommended to support this speculation.
Conclusion
In conclusion, our study showed a significant reduction
of liver fibrosis following treatment with TELM, an AT1
receptor blocker and a PPARγ ligand, in a murine model
of hepatic fibrosis induced by S. mansoni infection. The
anti-fibrotic effect of this compound could be due todown-regulation of TGF-β1 as well as increasing the
hepatic expression of MMP-2 relative to TIMP-2.
Thus, its potential improvement of fibrotic markers
makes the drug a particularly strong candidate for
treating hepatic fibrosis. Moreover, TELM may be
more efficient than other AT1 receptor blockers such
as losartan or candesartan, in suppressing liver fibro-
sis, due to activation of PPARγ receptors besides AT1
receptor antagonism.
The RAS and the PPARγ receptors are important tar-
gets for the treatment of fibrosis. Searching for agents
that can affect multiple signalling pathways involved in
hepatic fibrosis is recommended. Additionally, testing
the efficacy as well as the safety of prolonged PZQ treat-
ment as an anti-fibrotic, independent of its anti-
helminthic activity, particularly in the late stages, is also
recommended. Finally, the effectiveness of TELM as a
choice for patients treated for hypertension or heart
failure associated with liver affection needs further
research.
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